ArticleBMC ophthalmology2025
Clinical characteristics and long-term outcomes of Vogt-Koyanagi-Harada disease in pediatric age group.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Vogt-Koyanagi-Harada Disease Presenting With Progressive Visual Loss and Multisystem Involvement: A Case Report.The American journal of case reports · 2026Article
- An Update and Overview of the Ocular and Extraocular Microbiome and Its Impact on Ophthalmic Care.Advances in therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of this retrospective study is to evaluate the clinical presentations and long-term outcomes of uveitis secondary to Vogt-Koyanagi-Harada (VKH) disease in children.
methodsFive pediatric patients diagnosed with VKH disease were analyzed with respect to their clinical characteristics, presenting signs and symptoms, complications, and long-term outcomes. The median follow-up duration was 8 years, providing rare longitudinal data in the pediatric VKH population.
resultsOcular findings at presentation included anterior chamber cells (6 eyes, 60%), keratic precipitates (3 eyes, 30%), posterior synechiae (4 eyes, 40%), depigmented scars (4 eyes, 40%), disc edema (1 eye, 10%), exudative retinal detachment (2 eyes, 20%) and 'sunset-glow' fundus (4 eyes, 40%). The mean best corrected visual acuity improved from 20/32 to 20/25 at last follow-up. Complications were observed in several cases, including cataracts (40%), glaucoma (20%), and choroidal neovascularization (30%). Systemic corticosteroids and immunosuppressants were used in all patients, with varied treatment responses and recurrence rates. Two patients required surgical intervention for cataracts and glaucoma.
conclusionPediatric VKH patients are prone to significant complications such as cataracts, glaucoma, and choroidal neovascularization. Despite these complications, appropriate use of systemic corticosteroids and immunosuppressants can lead to favorable visual outcomes. Long-term careful monitoring is essential to manage recurrences, complications and prevent vision-threatening complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.